Madrigal Pharma (MDGL) Tops Q3 EPS by $1.84, Beats on Revenue

Madrigal Pharma (NASDAQ: MDGL) reported Q3 EPS of ($4.92), $1.84 better than the analyst estimate of ($6.76). Revenue for the quarter came in at $62.2 million versus the consensus estimate of $34.09 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Trump says North Korea's Kim responded to his outreach
• Paramount seeks $1.88B bond from state AGs to cover costs of WBD merger delay - CNBC